Arrhythmias caused by ondansetron: Case report

Authors

  • Juan M. Chala Tandrón
  • Liset Jiménez Fernández
  • Zoila Armada Esmores
  • Yudileidy Brito Ferrer
  • Melba Zayas González
  • Maiyen García Arcia

Abstract

The ondansetron is used to prevent nausea and vomiting caused by chemotherapy, radiotherapy and surgery, belonging to the serotonin 5-HT3 receptor antagonists, a natural substance that can cause nausea and vomiting, and it blocks its action. The ondansetron is packaged in the form of rapid disintegration tablets, as a solution to be taken orally and in ampules, for parenteral use. The case of a 67-year-old female patient is presented, with a diagnosis of breast carcinoma, who underwent radical mastectomy with axillary dissection was performed, and who received chemotherapy with adriamycin, cyclophosphamide and paclitaxel; as well as ondansetron to treat nausea and vomiting. The patient presented a wide QRS complex tachycardia after taking the drug.

Downloads

Download data is not yet available.

References

1. Morón Rodríguez FJ, Levi Rodríguez M. Farmacología General. La Habana: Ciencias Médicas; 2002.

2. Flórez J, Armijo JA, Mediavilla A. Farmacología humana. 6ª ed. Barcelona: Elsevier España; 2014.

3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.

4. Brião FF, Horta ML, Horta BL, de Barros GA, Behrensdorf AP, Severo I, et al. Comparison of droperidol and ondansetron prophylactic effect on subarachnoid morphine-induced pruritus. Braz J Anesthesiol. 2015 Jul-Aug;65(4):244-8.

5. Ministerio de Salud Pública. Formulario Nacional de Medicamentos. La Habana: Editorial Ciencias Médicas; 2014.

6. Tricco AC, Soobiah C, Antony J, Hemmelgarn B, Moher D, Hutton B, et al. Safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery and chemotherapy: protocol for a systematic review and network meta-analysis. Syst Rev [Internet]. 2013 [citado 31 Mar 2019];2:46. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702491/pdf/2046-4053-2-46.pdf

7. McKechnie K, Froese A. Ventricular tachycardia after ondansetron administration in a child with undiagnosed long QT syndrome. Can J Anesth. 2010;57(5):453-7.

8. Buyukavci M, Olgun H, Ceviz N. The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. Am J Clin Oncol. 2005;28(2):201-4.

9. Freedman SB, Hall M, Shah SS, Kharbanda AB, Aronson PL, Florin TA, et al. Impact of increasing ondansetron use on clinical outcomes in children with gastroenteritis. JAMA Pediatr. 2014;168(4):321-9.

10. Brenner SM, Boucher J. Fatal Cardiac Arrest in 2 Children: Possible Role of Ondansetron. Pediatr Emerg Care. 2016;32(11):779-84.

11. Faria C, Li X, Nagl N, McBride A. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014;7(1):50-8.

12. Schwartzberg L, Barbour SY, Morrow GR, Ballinari G, Thorn MD, Cox D. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV). Support Care Cancer. 2014;22(2):469-77.

Downloads

Published

2019-04-06

How to Cite

1.
Chala Tandrón JM, Jiménez Fernández L, Armada Esmores Z, Brito Ferrer Y, Zayas González M, García Arcia M. Arrhythmias caused by ondansetron: Case report. CorSalud [Internet]. 2019 Apr. 6 [cited 2025 Jul. 2];11(2):171-4. Available from: https://revcorsalud.sld.cu/index.php/cors/article/view/455

Issue

Vol. 11 No. 2 (2019)

Section

CASE REPORTS

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.